Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PMV Pharmaceuticals
Biotech
PMV plots ovarian cancer filing after seeing midphase data
PMV reported a 43% response rate in ovarian cancer, putting the biotech on a track it believes will lead to a filing for FDA approval in 2027.
Nick Paul Taylor
Sep 10, 2025 9:40am
PMV lays off 30% to fund ph. 2 trial of solid tumor drug
Jan 19, 2024 8:29am
PMV Pharma nabs $70M for tumor suppressor programs
Aug 3, 2020 10:45pm
Chutes & Ladders—AZ research exec jumps to startup Goldfinch
Dec 8, 2017 8:20am
Cancer startup PMV Pharma gains impressive $74M B round
Feb 22, 2017 8:21am
